Join our daily newsletter At The Bell to receive exclusive market insights
- Medical technology company Nova Eye Medical (EYE) begins the commercial roll-out of its iTrack Advance device across select markets in Europe and the Asia Pacific
- Initial orders have already been made and the first shipments have been sent to surgeons
- The iTrack Advance is a consumable surgical device for glaucoma and is designed to improve the efficiency of the canaloplasty procedure
- Nova Eye expects the iTrack Advance will increase the number of surgeons undertaking the canaloplasty procedure
- Nova Eye is up 4.76 per cent on the market with shares trading at 22 cents at 3:52 pm AEST
Medical technology company Nova Eye Medical (EYE) has begun the commercial roll-out of its iTrack Advance device across select markets in Europe and the Asia Pacific.
Initial orders have already been made and the first shipments have been sent to surgeons.
The iTrack Advance is a consumable surgical device for glaucoma (a group of eye conditions that can cause blindness) and is designed to improve the efficiency of the canaloplasty procedure.
Canaloplasty is performed to reduce the intraocular pressure in patients affected by glaucoma.
iTrack Advance combines Nova Eye’s iTrack microcatheter technology with a custom-designed cannula (a thin tube) and handheld injector.
It features an illuminated fibre optic tip that allows the surgeon to continuously monitor the location of the microcatheter.
Nova Eye expects the iTrack Advance will increase the number of surgeons undertaking the canaloplasty procedure.
“We are very excited that the roll-out of the iTrack Advance has begun. With a number of industry-leading features and backed by a strong IP portfolio, we expect iTrack Advance to drive improved sales performance for the group during the 2023 fiscal year,” Managing Director Tom Spurling said.
“Across most of our global markets, we have noted a marked increase in surgeon interest in canaloplasty. The introduction of the iTrack Advance underscores our commitment to grow the canaloplasty field.”
Nova Eye was up 4.76 per cent on the market with shares trading at 22 cents at 3:52 pm AEST.
